Cantor Fitzgerald Reaffirms Their Buy Rating on AnaptysBio Inc (ANAB)

Cantor Fitzgerald analyst Eliana Merle reiterated a Buy rating on AnaptysBio Inc (NASDAQ: ANAB) today and set a price target of $124. The company’s shares opened today at $92.80. Merle wrote: “. More »

Analysts Offer Insights on Healthcare Companies: Spark Therapeutics (NASDAQ: ONCE) and Xoma Corp (NASDAQ: XOMA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Spark Therapeutics (NASDAQ:ONCE) and Xoma Corp (NASDAQ:XOMA). Spark Therapeutics (ONCE) William Blair analyst Raju Prasad More »